Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial-Reference-Cited by-同舟云学术

Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial

Published:2008-08 Issue:9637 Volume:372 Page:449-456
ISSN:0140-6736
Container-title:The Lancet
language:en
Short-container-title:The Lancet

Author:

Motzer Robert J,Escudier Bernard,Oudard Stéphane,Hutson Thomas E,Porta Camillo,Bracarda Sergio,Grünwald Viktor,Thompson John A,Figlin Robert A,Hollaender Norbert,Urbanowitz Gladys,Berg William J,Kay Andrea,Lebwohl David,Ravaud Alain

Publisher

Elsevier BV

Subject

General Medicine

Reference24 articles.

1. The von Hippel-Lindau tumor suppressor gene and kidney cancer;Kaelin;Clin Cancer Res,2004

2. Renal cell carcinoma—molecular pathways and therapies;Brugarolas;N Engl J Med,2007

3. TSC2 regulates VEGF through mTOR-dependent and -independent pathways;Brugarolas;Cancer Cell,2003

4. Hypoxia-inducible factor determines sensitivity to inhibitors of mTOR in kidney cancer;Thomas;Nat Med,2006

5. Renal cell carcinoma;Motzer;N Engl J Med,1996

Cited by 2721 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Design and evaluation of novel inhibitors for the treatment of clear cell renal cell carcinoma;Bioorganic Chemistry;2024-10

2. Multifocal, multiphenotypic tumours arising from an MTOR mutation acquired in early embryogenesis;Oncogene;2024-09-13

3. Thymic epithelial tumor medical treatment: A narrative review;Biochimica et Biophysica Acta (BBA) - Reviews on Cancer;2024-09

4. Effect of Everolimus on Prognosis of Neurofibromatosis Type 1 Lesions: A Systematic Review and Meta Analysis;Clinical Therapeutics;2024-09

5. Adjuvant Everolimus in Patients with Completely Resected, Very High-risk Renal Cell Carcinoma of Clear Cell Histology: Results from the Phase 3 Placebo-controlled SWOG S0931 (EVEREST) Trial;European Urology;2024-09